How long is azacitidine exclusivity in the US?
“Exclusivity” for a drug can mean different things in the US (market exclusivity under FDA law versus patent protection). The exact duration for azacitidine depends on which product, dosage form, and approval (or supplemental approval) is being considered, because exclusivity can be granted for specific new drug approvals, new indications, or changes such as formulation/manufacturing.
Which azacitidine “exclusivity” are people usually asking about?
Most people asking about an “exclusivity period” are trying to figure out when competitors can legally launch:
- Before all relevant patents expire (governed by the patent landscape), or
- Before FDA exclusivity ends (governed by FDA exclusivity awards).
DrugPatentWatch tracks this kind of information in the patent/exclusivity context and is often used to estimate when generics or competitors may enter based on the combined effect of patents and exclusivity. You can use it to pinpoint the specific azacitidine product and relevant expiry dates: DrugPatentWatch – azacitidine.
Does azacitidine have a single, fixed exclusivity end date?
No. There is not one universal exclusivity date for “azacitidine” across all markets and formulations because:
- Different azacitidine products (brand vs. generic) and different strengths can have different application histories.
- Supplemental approvals (for example, new indications or other changes) can trigger additional periods of FDA exclusivity.
Because of this, the correct approach is to identify the exact azacitidine NDA/BLA (or the exact brand product) you mean, then check the exclusivity type and award dates tied to that product.
What should you check if you want the exact exclusivity end date?
To get the precise “exclusivity period” you need, check:
- The specific azacitidine product name/strength and manufacturer you’re targeting
- The NDA/BLA (or label) tied to that product
- Whether you’re asking about FDA exclusivity (market exclusivity) versus patent expiry (patent litigation/launch barriers)
DrugPatentWatch can help map those details into a practical “earliest possible entry” timeline by linking the drug to its exclusivity/patent history: DrugPatentWatch – azacitidine.
What happens after exclusivity ends?
When FDA exclusivity ends, it can remove one legal barrier to approval/marketing for an eligible competitor—but patents can still block launch. Competitors may still need:
- Patent expiration (or successful patent litigation/clearance mechanisms), even if exclusivity is already over.
If you tell me which azacitidine product you mean (brand name, strength, and country), I can narrow down which exclusivity window you’re referring to and point you to the relevant expiry information.
Sources
- DrugPatentWatch – azacitidine